120 related articles for article (PubMed ID: 16320725)
1. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.
Gupta S; Solomon JM; Tasciyan TA; Cao MM; Stone RD; Ostuni JL; Ohayon JM; Muraro PA; Frank JA; Richert ND; McFarland HF; Bagnato F
Mult Scler; 2005 Dec; 11(6):658-68. PubMed ID: 16320725
[TBL] [Abstract][Full Text] [Related]
2. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
Jeffery DR; Chepuri N; Durden D; Burdette J
Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
[TBL] [Abstract][Full Text] [Related]
3. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
Rao AB; Richert N; Howard T; Lewis BK; Bash CN; McFarland HF; Frank JA
Neurology; 2002 Sep; 59(5):688-94. PubMed ID: 12221158
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis.
Morgen K; Crawford AL; Stone RD; Martin R; Richert ND; Frank JA; McFarland HF
Mult Scler; 2005 Apr; 11(2):146-8. PubMed ID: 15794386
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
[TBL] [Abstract][Full Text] [Related]
7. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.
van den Elskamp IJ; Lembcke J; Dattola V; Beckmann K; Pohl C; Hong W; Sandbrink R; Wagner K; Knol DL; Uitdehaag B; Barkhof F
Mult Scler; 2008 Jul; 14(6):764-9. PubMed ID: 18611989
[TBL] [Abstract][Full Text] [Related]
8. The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.
Gaindh D; Jeffries N; Ohayon J; Richert ND; Pellicano C; Frank JA; McFarland H; Bagnato F
Expert Opin Biol Ther; 2008 Dec; 8(12):1823-9. PubMed ID: 18990070
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
10. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis.
Di Rezze S; Gupta S; Durastanti V; Millefiorini E; Pozzilli C; Bagnato F
Mult Scler; 2007 Apr; 13(3):343-7. PubMed ID: 17439903
[TBL] [Abstract][Full Text] [Related]
11. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.
Richert ND; Zierak MC; Bash CN; Lewis BK; McFarland HF; Frank JA
Mult Scler; 2000 Apr; 6(2):86-90. PubMed ID: 10773853
[TBL] [Abstract][Full Text] [Related]
12. A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis.
Gulati A; Bagnato F; Villoslada P; Velez de Mendizabal N
CPT Pharmacometrics Syst Pharmacol; 2015 May; 4(5):295-304. PubMed ID: 26225255
[TBL] [Abstract][Full Text] [Related]
13. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
Kita M; Goodkin DE; Bacchetti P; Waubant E; Nelson SJ; Majumdar S
Neurology; 2000 May; 54(9):1741-5. PubMed ID: 10802778
[TBL] [Abstract][Full Text] [Related]
14. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.
Frank JA; Richert N; Bash C; Stone L; Calabresi PA; Lewis B; Stone R; Howard T; McFarland HF
Neurology; 2004 Mar; 62(5):719-25. PubMed ID: 15007120
[TBL] [Abstract][Full Text] [Related]
16. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Smith DR; Weinstock-Guttman B; Cohen JA; Wei X; Gutmann C; Bakshi R; Olek M; Stone L; Greenberg S; Stuart D; Orav J; Stuart W; Weiner H
Mult Scler; 2005 Oct; 11(5):573-82. PubMed ID: 16193896
[TBL] [Abstract][Full Text] [Related]
17. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
18. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
19. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
20. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
